Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease

Renal Failure

Volumn 26, Issue 4, 2004, Pages 411-418

  Yasuda, Gen ^a   Kuji, Tadashi ^a   Hasegawa, Kyoko ^a   Ogawa, Nariaki ^a   Shimura, Gaku ^a   Ando, Daisaku ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Creatine kinase; Myoglobin; Myopathy; Rhabdomyolysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; CREATININE; FLUINDOSTATIN; FRUCTOSE BISPHOSPHATE ALDOLASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOGLOBIN; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIET THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ADULT; AGED; ALBUMINURIA; CHRONIC DISEASE; CREATININE; DIABETIC NEPHROPATHIES; FATTY ACIDS, MONOUNSATURATED; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INDOLES; MALE; MIDDLE AGED; MYOGLOBIN; PROSPECTIVE STUDIES;

EID: 4444266049     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120039826     Document Type: Article

References (24)

1. Wanner, C.; Hörl, W.H.; Luley, C.H.; Wieland, H. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int. 1991, 39 (4), 754-760.
2. Jokubaitis, L.A. Development and pharmacology of fluvastatin. Br. J. Clin. Pract. 1996, S77A, 11-15.
3. Friedewald, W.T.; Levy, R.I.; Fredrickson, S. Estimate of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499-504.
4. Tochikubo, O.; Uneda, S.; Kaneko, Y. Simple portable device for sampling a whole day's urine and its application to hypertensive outpatients. Hypertension 1983, 5 (2), 270-274.
5. Kalafsky, G.; Smith, H.T.; Choc, M.G. High-performance liquid chromatographic method for the determination of fluvastatin in human plasma. J. Chromatogr. 1993, 614 (2), 307-313.
6. Lintott, C.J.; Scott, R.S.; Bremer, J.M.; Shand, B.I. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am. J. Cardiol. 1995, 76 (2), 97A-101A.
7. Matzkies, F.K.; Bahner, U.; Teschner, M.; Hohage, H.; Heidland, A.; Schaefer, R.M. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am. J. Nephrol. 1999, 19 (4), 492-494.
8. Buemi, M.; Allegra, A.; Corica, F.; Aloisi, C.; Giacobbe, M.; Pettinato, G.; Corsonello, A.; Senatore, M.; Frisina, N. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin. Pharmacol. Ther. 2000, 67 (4), 427-431.
9. Rabelink, A.J.; Hené, R.J.; Erkelens, D.W.; Joles, J.A.; Koomans, H.A. Partial remission of nephrotic syndrome in patient on long-term simvastatin. Lancet 1990, 335 (8696), 1045-1046.
10. Chan, P.C.K.; Robinson, J.D.; Yeung, W.C.; Cheng, I.K.P.; Yeung, H.W.D.; Tsang, M.T.S. Lovastatin in glomerulonephritis patients with hyperlipidemia and heavy proteinuria. Nephrol. Dial. Transplant. 1992, 7 (2), 93-99.
11. Tonolo, G.; Ciccarese, M.; Brizzi, P.; Puddu, L.; Secchi, G.; Calvia, P.; Atzeni, M.M.; Melis, M.G.; Maioli, M. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997, 20 (12), 1891-1895.
12. Jandeleit-Dahm, K.; Cao, Z.; Cox, A.J.; Kelly, D.J.; Gilbert, R.E.; Cooper, M.E. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int. 1999, 56 (Suppl. 71), S-31-S-36.
13. Fried, L.F.; Orchard, T.J.; Kasiske, B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001, 59 (1), 260-269.
14. Tobert, J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 1988, 62 (15), 28J-34J.
15. Benghozi, R.; Bortolini, M.; Jia, Y.; Isaacsohn, J.L.; Troendle, A.J.; Gonasun, L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am. J. Cardiol. 2002, 89 (2), 231-233.
16. Arnadottir, M.; Eriksson, L.O.; Thysell, H.; Karkas, J.D. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993, 65 (3), 410-413.
17. Regazzi, M.B.; Iacona, I.; Campana, C.; Raddato, V.; Lesi, C.; Perani, G.; Gavazzi, A.; Viganò, M. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant. Proc. 1993, 25 (4), 2732-2734.
18. Hamelin, B.A.; Turgeon, J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. TIPS 1998, 19 (1), 26-37.
19. Omar, M.A.; Wilson, J.P.; Cox, T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother. 2001, 35 (9), 1096-1107.
20. Stern, R.H.; Yang, B.B.; Horton, M.; Moore, S.; Abel, R.B.; Olson, S.C. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J. Clin. Pharmacol. 1997, 37 (9), 816-819.
21. Transon, C.; Leemann, T.; Dayer, P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 1996, 50 (3), 209-215.
22. Stirling, C.M.; Isles, C.G. Rhabdomyolysis due to simvastatin in a transplant patient: are some statins safer than others? Nephrol. Dial. Transplant. 2001, 16 (4), 873-874.
23. Smith, H.T.; Jokubaitis, L.A.; Troendle, A.J.; Hwang, D.S.; Robinson, W.T. Pharmacokinetics of fluvastatin and specific drug interactions. Am. J. Hypertens. 1993, 6 (11), 375S-382S.
24. Tse, F.L.S.; Jaffe, J.M.; Troendle, A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol. 1992, 32 (7), 630-638.